Business context and reporting period
Simulations Plus, Inc. provides biosimulation software and consulting services for drug discovery, development, research, and regulatory submissions. This Form 10-Q covers the third quarter and first nine months of fiscal 2024, ended May 31, 2024; comparisons are with the same periods in fiscal 2023. The company reports Software and Services segments.
Financial results and liquidity
- Third-quarter revenue: $18.5 million, up 14% year over year. Software revenue rose 12% to $11.9 million; Services revenue rose 18% to $6.6 million.
- Third-quarter profitability: Gross profit was $13.3 million, approximately flat, while gross margin fell to 71% from 82%. Operating income declined 54% to $1.9 million. Net income fell 22% to $3.1 million; diluted EPS was $0.15 versus $0.20.
- Nine-month results: Revenue increased 17% to $51.3 million; gross profit rose 2% to $36.3 million, with gross margin down to 71% from 81%. Operating income declined 19% to $7.3 million; net income decreased 3% to $9.1 million. Diluted EPS was $0.45 versus $0.46.
- Segment margins: Third-quarter Software gross margin was 88% versus 91%; Services was 41% versus 63%. For nine months, Software margin was 88% versus 90%, and Services was 44% versus 66%.
- Cash flow: Nine-month operating cash flow was $11.7 million, down from $18.8 million. Investing activities provided $45.5 million, primarily reflecting investment maturities and sales, partly offset by purchases and software development costs. Financing used $5.6 million, including dividends and a $2.5 million Immunetrics earnout payment.
- Balance sheet at May 31: Cash and cash equivalents were $109.1 million, short-term investments $9.9 million, working capital $124.3 million, and total assets $192.7 million. Total liabilities were $11.8 million; no conventional borrowings are reported. Liabilities include leases and acquisition-related contracts payable.
- Other metrics: Remaining performance obligations were $10.5 million, of which 96% was expected to be recognized over the next 12 months. The company declared $0.18 per share in dividends during the nine-month period.
Material changes and unusual items
- Revenue growth reflected higher software sales and increased consulting services, including Immunetrics-related QSP services. Software growth included GastroPlus, Monolix, QSP, and ADMET Predictor.
- Services costs rose substantially, including added scientific headcount, compensation increases, and Immunetrics-related costs. The company also reorganized departments, moving services personnel into cost of revenues; this shifted $2.4 million of nine-month costs from G&A to cost of revenues and affects period-to-period comparability.
- Other income increased, supported by interest income and a favorable change in the fair value of Immunetrics contingent consideration. These items partly offset lower operating income.
- On June 11, 2024, after the quarter ended, the company acquired Pro-ficiency for $100 million in cash, subject to post-closing adjustments. Pro-ficiency provides simulation-based learning, intelligence, and compliance solutions. Its results will be included in future consolidated periods.
- The board declared a final quarterly dividend of $0.06 per share, payable August 5, 2024, and decided to discontinue quarterly dividends thereafter to redirect capital toward growth initiatives. The company also had $30 million remaining under its share repurchase authorization, with no repurchases in the nine-month period.
Outlook, risks, and contingencies
Management expects existing cash, investments, operating cash generation, and working capital to fund operations and commitments for at least the next 12 months. The filing provides no numeric revenue or earnings guidance. Management sees continued potential demand for simulation and modeling tools, but notes that customer delays, program holds or cancellations, pharmaceutical-industry consolidation, competition, economic uncertainty, and the uncertain acceptance of new products could affect results.
The Pro-ficiency acquisition used a significant portion of cash reserves and brings potential transaction, integration, performance, and undisclosed-liability risks. The company expects additional integration costs, which may be difficult to estimate. A representation-and-warranty insurance policy provides up to $10 million of coverage, subject to exclusions and a $0.5 million retention; the filing also describes escrow arrangements. No pending or threatened legal proceedings were reported. No impairment losses were recorded in the periods presented.
Key facts for investors to verify
- Track whether Pro-ficiency integration, acquisition costs, and performance meet expectations, and review post-acquisition cash and liquidity levels.
- Assess whether Services gross margins recover as staffing and the reorganized business-unit structure mature; distinguish operating trends from classification changes.
- Evaluate the sustainability of earnings given lower operating income and the contribution of interest income and contingent-consideration remeasurement to other income.
- Confirm the timing and conversion of the $10.5 million remaining performance obligations, and monitor customer demand, project delays, and renewals.
- Review future capital allocation after the dividend discontinuation, including growth investment, acquisitions, and any use of the remaining repurchase authorization.